Literature DB >> 23496660

EGFR tyrosine kinase regulates human small-conductance Ca2+-activated K+ (hSKCa1) channels expressed in HEK-293 cells.

Wei Wu1, Hai-Ying Sun, Xiu-Ling Deng, Gui-Rong Li.   

Abstract

SKCa (small-conductance Ca(2+)-activated K(+)) channels are widely distributed in different tissues, including the brain, pancreatic islets and myocardium and play an important role in controlling electrical activity and cellular functions. However, intracellular signal modulation of SKCa channels is not fully understood. The present study was designed to investigate the potential regulation of hSKCa1 (human SKCa1) channels by PTKs (protein tyrosine kinases) in HEK (human embryonic kidney)-293 cells expressing the hSKCa1 (KCNN1) gene using approaches of whole-cell patch voltage-clamp, immunoprecipitation, Western blotting and mutagenesis. We found that the hSKCa1 current was inhibited by the broad-spectrum PTK inhibitor genistein, the selective EGFR (epidermal growth factor receptor) kinase inhibitors T25 (tyrphostin 25) and AG556 (tyrphostin AG 556), but not by the Src-family kinases inhibitor PP2. The inhibitory effect of these PTK inhibitors was significantly antagonized by the PTP (protein tyrosine phosphatase) inhibitor orthovanadate. The tyrosine phosphorylation level of hSKCa1 channels was reduced by genistein, T25 or AG556. The reduced tyrosine phosphorylation was countered by orthovanadate. Interestingly, the Y109F mutant hSKCa1 channel lost the inhibitory response to T25 or AG556, and showed a dramatic reduction in tyrosine phosphorylation levels and a reduced current density. These results demonstrate the novel information that hSKCa1 channels are inhibited by genistein, T25 and AG556 via EGFR tyrosine kinase inhibition, which is related to the phosphorylation of Tyr(109) in the N-terminus. This effect may affect electrical activity and cellular functions in brain, pancreatic islets and myocardium.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23496660     DOI: 10.1042/BJ20121324

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  6 in total

1.  Genistein and tyrphostin AG556 decrease ultra-rapidly activating delayed rectifier K+ current of human atria by inhibiting EGF receptor tyrosine kinase.

Authors:  Guo-Sheng Xiao; Yan-Hui Zhang; Wei Wu; Hai-Ying Sun; Yan Wang; Gui-Rong Li
Journal:  Br J Pharmacol       Date:  2017-02-09       Impact factor: 8.739

2.  Neurite Outgrowth Stimulated by Oxytocin Is Modulated by Inhibition of the Calcium Voltage-Gated Channels.

Authors:  M Zatkova; A Reichova; Z Bacova; V Strbak; A Kiss; J Bakos
Journal:  Cell Mol Neurobiol       Date:  2017-05-10       Impact factor: 5.046

3.  Genistein inhibited ammonia induced astrocyte swelling by inhibiting NF-κB activation-mediated nitric oxide formation.

Authors:  Hongliang Dai; Guizhi Jia; Wei Wang; Chunguang Liang; Siyu Han; Minghui Chu; Xifan Mei
Journal:  Metab Brain Dis       Date:  2017-03-03       Impact factor: 3.584

4.  The Natural Flavone Acacetin Blocks Small Conductance Ca2+-Activated K+ Channels Stably Expressed in HEK 293 Cells.

Authors:  Kui-Hao Chen; Hui Liu; Hai-Ying Sun; Man-Wen Jin; Guo-Sheng Xiao; Yan Wang; Gui-Rong Li
Journal:  Front Pharmacol       Date:  2017-10-10       Impact factor: 5.810

5.  Tyrphostin AG556 increases the activity of large conductance Ca2+ -activated K+ channels by inhibiting epidermal growth factor receptor tyrosine kinase.

Authors:  Yan Wang; Hai-Ying Sun; Ying-Guang Liu; Zheng Song; Gang She; Guo-Sheng Xiao; Yan Wang; Gui-Rong Li; Xiu-Ling Deng
Journal:  J Cell Mol Med       Date:  2017-03-14       Impact factor: 5.310

6.  The mineralocorticoid receptor leads to increased expression of EGFR and T-type calcium channels that support HL-1 cell hypertrophy.

Authors:  Katharina Stroedecke; Sandra Meinel; Fritz Markwardt; Udo Kloeckner; Nicole Straetz; Katja Quarch; Barbara Schreier; Michael Kopf; Michael Gekle; Claudia Grossmann
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.